Alopecia Areata Prevalence in Australia: Insights From a Nationally Representative Cross‐Sectional Survey Study
Australasian Journal of Dermatology · 2026
DOI: 10.1111/ajd.70137 ↗Kurz gefasst
Fachartikel in der Zeitschrift Australasian Journal of Dermatology, 2026. Verfasst von Rodney Sinclair und 9 weiteren Autor:innen. Beteiligte Einrichtung: Sinclair Dermatology, East Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Alopecia Areata. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer Australia Pty Ltd.
Abstract (Originalsprache)
Background/Objectives To estimate the lifetime and point prevalence of alopecia areata (AA) among Australians aged ≥ 15 years.
Methods
A cross‐sectional survey was conducted from August to September 2024 in a quota‐balanced sample of the Australian population, aged ≥ 12 years (exploratory objective included participants aged 12–14 years). Participants completed the Alopecia Assessment Tool (ALTO) to identify AA. Participants with AA completed the Scalp Hair Assessment Patient‐Reported Outcome to assess hair loss and a questionnaire on hair loss experience. Lifetime prevalence was calculated as the proportion of participants with AA per the ALTO, and point prevalence was calculated as the proportion of participants with AA per the ALTO and current scalp hair loss.
Results
Of 8,256 participants, 194 had potential AA, and of those, 188 were aged ≥ 15 years. The lifetime prevalence (95% CI) of AA among those aged ≥ 15 years ranged from 1.2% (1.08–1.32) to 2.3% (2.13–2.47), with a point prevalence (95% CI) of 0.9% (0.79–1.01) to 1.4% (1.27–1.53). Of 194 participants with potential AA, 125 had healthcare provider (HCP)‐diagnosed AA and 69 had self‐diagnosed AA. More self‐diagnosed participants had active hair loss than HCP‐diagnosed participants. Thirty‐nine HCP‐diagnosed participants (31.2%) were not using any treatment/management approach, and of those, 23.1% were unaware of treatment/management options. Most self‐diagnosed participants were using shampoos/conditioners recommended for hair loss (62.3%).
Conclusions
There is a need for improved AA education in Australia to increase awareness, given that approximately 36% of participants were self‐diagnosed and 31% of HCP‐diagnosed participants were not using treatment or a management approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sinclair Dermatology, East Melbourne, Victoria, Australia.
- Skin Partners, Brisbane, Queensland, Australia.
- IQVIA Solutions Australia, North Sydney, New South Wales, Australia.
- Pfizer Australia, Sydney, New South Wales, Australia.
- Motor Neuron Disease Research Centre, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.
ORCID-Profile: Rodney Sinclair, Maureen Hitschfeld, Christoph Lohan
Förderung
- Pfizer Australia Pty Ltd
Zitieren
APA
Sinclair, R., Eisman, S., Yip, L., Hitschfeld, M., Williamson, A., Stratton, G., Lohan, C., Lee, C. M. Y., Kapoor, K., & Pereira, C. D. F. (2026). Alopecia Areata Prevalence in Australia: Insights From a Nationally Representative Cross‐Sectional Survey Study. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.70137
Vancouver
Sinclair R, Eisman S, Yip L, Hitschfeld M, Williamson A, Stratton G, et al. Alopecia Areata Prevalence in Australia: Insights From a Nationally Representative Cross‐Sectional Survey Study. Australasian Journal of Dermatology. 2026. doi:10.1111/ajd.70137
BibTeX
@article{Sinclair2026,
author = {Sinclair, Rodney and Eisman, Samantha and Yip, Leona and Hitschfeld, Maureen and Williamson, Anna and Stratton, Giles and Lohan, Christoph and Lee, Carol M Y and Kapoor, Komal and Pereira, Candida da Fonseca},
title = {Alopecia Areata Prevalence in Australia: Insights From a Nationally Representative Cross‐Sectional Survey Study},
journal = {Australasian Journal of Dermatology},
year = {2026},
doi = {10.1111/ajd.70137}
}
EUVIMED